| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
The release of LPS-activated reactive oxygen species (ROS) and nitric oxide (NO) from RAW264.7 cells is inhibited by moracin C (1-50 μM, 24 hours) [1]. Moracin C inhibits RAW264 at 1–50 μM for 2 hours. Pro-inflammatory cytokines (IL-1β, IL-6, and TNF) in LPS-activated RAW 264.7 cells 7 cells The mRNA and protein expression of iNOS and COX-2 are inhibited by moracin C (1-50 μM, 2 h) [1]. The phosphorylation of p38, ERK, and JNK in LPS-activated RAW 264.7 cells is inhibited by moracin C (1-50 μM, 2 hours) [1]. Creation of
|
|---|---|
| ln Vivo |
Moracin C (100 mg/kg, gavage, mice) is rapidly and well absorbed within the body, and is widely distributed in the gastrointestinal tract, liver, kidneys and liver [2].
|
| Cell Assay |
RT-PCR[1]
Cell Types: RAW -α)[1]. 264.7 Macrophage Tested Concentrations: 1, 10, 25, 50 μM Incubation Duration: 2 hrs (hours) Experimental Results: Inhibited LPS-induced iNOS and COX-2 mRNA expression. Western Blot Analysis[1] Cell Types: RAW 264.7 Macrophage Tested Concentrations: 1, 10, 25, 50 μM Incubation Duration: 2 h Experimental Results: Inhibited LPS-induced TLR4 expression and NF-κB activation. Levels of phosphorylated p38, ERK and JNK were diminished. |
| Animal Protocol |
Animal/Disease Models: Mouse (PK Assay) [2]
Doses: 100 mg/kg Route of Administration: po (oral gavage) Experimental Results: pharmacokinetic/PK/PK characteristics of Moracin C. Parameters Terminal half-life (min) Cmax (μg/mL) Tmax (min) CLR (mL/min/kg) 100 mg/kg 256 1.79 15 0.032 |
| References | |
| Additional Infomation |
Moracin C is a member of benzofurans.
Moracin C has been reported in Morus cathayana, Morus wittiorum, and other organisms with data available. |
| Molecular Formula |
C19H18O4
|
|---|---|
| Molecular Weight |
310.349
|
| Exact Mass |
310.12
|
| Elemental Analysis |
C, 73.53; H, 5.85; O, 20.62
|
| CAS # |
69120-06-5
|
| PubChem CID |
155248
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
439.4±35.0 °C at 760 mmHg
|
| Melting Point |
198 - 199 °C
|
| Flash Point |
219.6±25.9 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.664
|
| LogP |
4.46
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
419
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZTGHWUWBQNCCOH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H18O4/c1-11(2)3-6-15-16(21)7-13(8-17(15)22)18-9-12-4-5-14(20)10-19(12)23-18/h3-5,7-10,20-22H,6H2,1-2H3
|
| Chemical Name |
1,3-Benzenediol, 5-(6-hydroxy-2-benzofuranyl)-2-(3-methyl-2-buten-1-yl)-
|
| Synonyms |
Moracin C;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~805.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2222 mL | 16.1108 mL | 32.2217 mL | |
| 5 mM | 0.6444 mL | 3.2222 mL | 6.4443 mL | |
| 10 mM | 0.3222 mL | 1.6111 mL | 3.2222 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
